Sage Journals: Discover world-class research

Open access

Research article

First published 2022

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation

Olivier Corbeil, Anne-Marie Essiambre, Laurent Béchard [...]

Therapeutic Advances in Psychopharmacology

Open access

Research article

First published 2020

Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia

Maria Paz Garcia-Portilla, Pierre-Michel Llorca, Giuseppe Maina [...]

Therapeutic Advances in Psychopharmacology

Open access

Research article

First published 2020

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

Katalin Pungor, Vasilis P. Bozikas, Robin Emsley [...]

Therapeutic Advances in Psychopharmacology

Open access

Research article

First published 2011-8

Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial

Cynthia A. Bossie, Dong-Jing Fu, Jennifer Kern Sliwa [...]

Therapeutic Advances in Psychopharmacology

Open access

Research article

First published 2023

Preliminary data from a 4-year mirror-image and multicentre study of patients initiating paliperidone palmitate 6-monthly long-acting injectable antipsychotic: the Paliperidone 2 per Year study

Juan Antonio García-Carmona, Alba García-Pérez, Guillermo Isidro García [...]

Therapeutic Advances in Psychopharmacology

Retricted access

Research article

First published 2023-2

Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia: A comparative study in the Australian context

Nagesh Pai, Andrew B McGeachie, Andrea Puig [...]

Australasian Psychiatry

Open access

Research article

First published 2020

Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study

Sofia Pappa, Katy Mason

Therapeutic Advances in Psychopharmacology

Search results

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation

Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial

Preliminary data from a 4-year mirror-image and multicentre study of patients initiating paliperidone palmitate 6-monthly long-acting injectable antipsychotic: the Paliperidone 2 per Year study

Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia: A comparative study in the Australian context

Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study